The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice

被引:209
作者
Kim, Yuri [1 ]
Phan, Dillon [1 ]
Van Rooij, Eva [1 ]
Wang, Da-Zhi [1 ]
McAnally, John [1 ]
Qi, Xiaoxia [1 ]
Richardson, James A. [1 ,2 ]
Hill, Joseph A. [3 ]
Bassel-Duby, Rhonda [1 ]
Olson, Eric N. [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
关键词
D O I
10.1172/JCI33255
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The adult heart responds to excessive neurohumoral signaling and workload by a pathological growth response characterized by hypertrophy of cardiomyocytes and activation of a fetal program of cardiac gene expression. These responses culminate in diminished pump function, ventricular dilatation, wall thinning, and fibrosis, and can result in sudden death. Myocyte enhancer factor-2 (MEF2) transcription factors serve as targets of the signaling pathways that drive pathological cardiac remodeling, but the requirement for MEF2 factors in the progression of heart disease in vivo has not been determined. MEF2A and MEF2D are the primary MEF2 factors expressed in the adult heart. To specifically determine the role of MEF2D in pathological cardiac remodeling, we generated mice with a conditional MEF2D allele. MEF2D-null mice were viable, but were resistant to cardiac hypertrophy, fetal gene activation, and fibrosis in response to pressure overload and P-chronic adrenergic stimulation. Furthermore, we show in a transgenic mouse model that forced overexpression of MEF2D was sufficient to drive the fetal gene program and pathological remodeling of the heart. These results reveal a unique and important function for MEF2D in stress-dependent cardiac growth and reprogramming of gene expression in the adult heart.
引用
收藏
页码:124 / 132
页数:9
相关论文
共 40 条
[1]  
ARNOLD MA, 2007, J CLIN INVEST, V12, P377
[2]   Control of cardiac growth by histone acetylation/deacetylation [J].
Backs, J ;
Olson, EN .
CIRCULATION RESEARCH, 2006, 98 (01) :15-24
[3]   Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma [J].
Bai, Xueli ;
Wu, Lihua ;
Liang, TingBo ;
Liu, ZhiQiang ;
Li, JunJian ;
Li, DongLin ;
Xie, HaiYang ;
Yin, ShengYong ;
Yu, Jun ;
Lin, Qi ;
Zheng, ShuSen .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (01) :83-91
[4]   Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins [J].
Black, BL ;
Olson, EN .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1998, 14 :167-196
[5]   Balancing contractility and energy production: The role of myocyte enhancer factor 2 (MEF2) in cardiac hypertrophy [J].
Czubryt, MP ;
Olson, EN .
RECENT PROGRESS IN HORMONE RESEARCH, VOL 59, 2004, 59 :105-124
[6]   Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis [J].
Du, Y ;
Spence, SE ;
Jenkins, NA ;
Copeland, NG .
BLOOD, 2005, 106 (07) :2498-2505
[7]  
EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251
[8]   Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number [J].
Flavell, SW ;
Cowan, CW ;
Kim, TK ;
Greer, PL ;
Lin, YX ;
Paradis, S ;
Griffith, EC ;
Hu, LS ;
Chen, CF ;
Greenberg, ME .
SCIENCE, 2006, 311 (5763) :1008-1012
[9]   Cardiac hypertrophy: The good, the bad and the ugly [J].
Frey, N ;
Olson, EN .
ANNUAL REVIEW OF PHYSIOLOGY, 2003, 65 :45-79
[10]   Hypertrophy of the heart - A new therapeutic target? [J].
Frey, N ;
Katus, HA ;
Olson, EN ;
Hill, JA .
CIRCULATION, 2004, 109 (13) :1580-1589